15.83

15.83 (-0.10%)

As of Jun 14, 2022

Day One Biopharmaceuticals, Inc. [DAWN]

Source: 

Company Overview

We are a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically-defined cancers. Initially, we focus our clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. Our lead product candidate, DAY101 (tovorafenib), is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.

CountryUS
Headquartersbrisbanecalifornia
Phone Number(650) 484-0899
Industry
CEOJeremy Bender, Ph.D., M.B.A.
Websitedayonebio.com